← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

STXS logoStereotaxis, Inc.(STXS)Earnings, Financials & Key Ratios

STXS•AMEX
$1.92
$179M mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryMedical InstrumentsSub-IndustryRobotic and computer-assisted surgery
AboutStereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.Show more
  • Revenue$27M+0.5%
  • EBITDA-$24M-11.9%
  • Net Income-$24M-16.1%
  • EPS (Diluted)-0.30-11.1%
  • Gross Margin54.22%-2.3%
  • EBITDA Margin-88.31%-11.3%
  • Operating Margin-91.91%-12.7%
  • Net Margin-89.33%-15.5%
  • ROE-144.19%-87.4%
  • ROIC-289.62%-225.3%
  • Debt/Equity0.53+109.8%
Technical→

STXS Key Insights

Stereotaxis, Inc. (STXS) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

  • ✗Weak Piotroski F-Score: 2/9
  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 17 (bottom 17%)
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Trading more than 30% below 52-week high
  • ✗Expensive at 14.3x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

STXS Price & Volume

Stereotaxis, Inc. (STXS) stock price & volume — 10-year historical chart

Loading chart...

STXS Growth Metrics

Stereotaxis, Inc. (STXS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-2.59%
5 Years-1.41%
3 Years-8.4%
TTM19.61%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-9.54%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-3.38%

Return on Capital

10 Years-50.68%
5 Years-49.35%
3 Years-66.56%
Last Year-91.99%

STXS Recent Earnings

Stereotaxis, Inc. (STXS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
Mar 9, 2026
EPS
$0.06
Est $0.06
+0.0%
Revenue
$9M
Est $9M
-4.8%
Q4 2025
Nov 11, 2025
EPS
$0.03
Est $0.06
+50.0%
Revenue
$7M
Est $9M
-19.2%
Q3 2025
Aug 7, 2025
EPS
$0.05
Est $0.07
+28.6%
Revenue
$9M
Est $8M
+4.3%
Q2 2025
May 12, 2025
EPS
$0.07
Est $0.07
+0.0%
Revenue
$7M
Est $8M
-3.3%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMar 9, 2026
$0.06vs $0.06+0.0%
$9Mvs $9M-4.8%
Q4 2025Nov 11, 2025
$0.03vs $0.06+50.0%
$7Mvs $9M-19.2%
Q3 2025Aug 7, 2025
$0.05vs $0.07+28.6%
$9Mvs $8M+4.3%
Q2 2025May 12, 2025
$0.07vs $0.07+0.0%
$7Mvs $8M-3.3%
Based on last 12 quarters of dataView full earnings history →

STXS Peer Comparison

Stereotaxis, Inc. (STXS) competitors in Robotic and computer-assisted surgery — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
ISRG logoISRGIntuitive Surgical, Inc.Direct Competitor160.44B451.7357.4020.51%28.15%16.89%0.02
NVCR logoNVCRNovoCure LimitedDirect Competitor1.88B16.50-13.528.28%-25.66%-50.82%0.85
ABT logoABTAbbott LaboratoriesProduct Competitor149.97B86.2511.294.59%31.88%27.26%0.32
BSX logoBSXBoston Scientific CorporationProduct Competitor83.23B56.0028.8719.87%14.4%12.4%0.51
MDT logoMDTMedtronic plcProduct Competitor99.48B77.6021.503.62%13%9.45%0.59
IRTC logoIRTCiRhythm Technologies, Inc.Product Competitor3.87B117.70-84.6826.24%-3.53%-20.6%4.79
ATRC logoATRCAtriCure, Inc.Product Competitor1.42B28.01-116.7114.88%-0.83%-0.95%0.18
BEAT logoBEATHeartBeam, Inc.Product Competitor34.34M0.86-1.38-5.71%

Compare STXS vs Peers

Stereotaxis, Inc. (STXS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ISRG

Most directly comparable listed peer for STXS.

Scale Benchmark

vs ABT

Larger-name benchmark to compare STXS against a more recognizable public peer.

Peer Set

Compare Top 5

vs ISRG, NVCR, ABT, BSX

STXS Income Statement

Stereotaxis, Inc. (STXS) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Sales/Revenue32.16M31.14M29.35M28.9M26.63M35.02M28.15M26.77M26.92M30.07M
Revenue Growth %-14.63%-3.17%-5.77%-1.51%-7.86%31.51%-19.63%-4.89%0.55%19.61%
Cost of Goods Sold7.53M10.75M5.72M6.14M7.66M11.79M9.68M11.91M12.32M14.11M
COGS % of Revenue23.41%34.53%19.48%21.23%28.78%33.66%34.38%44.49%45.78%-
Gross Profit
24.63M▲ 0%
20.39M▼ 17.2%
23.63M▲ 15.9%
22.77M▼ 3.7%
18.97M▼ 16.7%
23.23M▲ 22.5%
18.47M▼ 20.5%
14.86M▼ 19.5%
14.59M▼ 1.8%
15.96M▲ 0%
Gross Margin %76.59%65.47%80.52%78.77%71.22%66.34%65.62%55.51%54.22%53.07%
Gross Profit Growth %-9.55%-17.23%15.89%-3.65%-16.69%22.49%-20.5%-19.55%-1.79%-
Operating Expenses31.06M26.31M26.09M27.59M25.68M36.12M37.25M36.7M39.33M40.05M
OpEx % of Revenue96.57%84.48%88.89%95.47%96.43%103.14%132.33%137.08%146.12%-
Selling, General & Admin25.57M21.55M17.87M18.57M17.54M25.92M26.69M26.43M29.57M31.08M
SG&A % of Revenue79.51%69.19%60.88%64.26%65.88%74.02%94.82%98.71%109.86%-
Research & Development5.49M4.76M8.22M9.02M8.14M10.2M10.56M10.27M9.76M9.46M
R&D % of Revenue17.06%15.29%28.01%31.21%30.56%29.12%37.51%38.37%36.26%-
Other Operating Expenses0212.03K0000000-492K
Operating Income
-6.43M▲ 0%
-5.92M▲ 7.9%
-2.46M▲ 58.5%
-4.83M▼ 96.5%
-6.71M▼ 39.1%
-12.89M▼ 92.0%
-18.78M▼ 45.7%
-21.84M▼ 16.3%
-24.74M▼ 13.3%
-24.09M▲ 0%
Operating Margin %-19.98%-19.01%-8.37%-16.7%-25.21%-36.8%-66.71%-81.58%-91.91%-80.1%
Operating Income Growth %-18.77%7.89%58.49%-96.45%-39.09%-91.96%-45.69%-16.31%-13.28%-
EBITDA-5.86M-5.17M-1.88M-4.7M-6.59M-12.78M-18.35M-21.24M-23.77M-22.55M
EBITDA Margin %-18.22%-16.59%-6.4%-16.28%-24.74%-36.5%-65.18%-79.35%-88.31%-75%
EBITDA Growth %-22.32%11.84%63.65%-150.48%-40.04%-94.03%-43.54%-15.79%-11.89%-4.07%
D&A (Non-Cash Add-back)566.93K753.68K579.02K122.74K126.21K106K429K595K969K1.53M
EBIT-6.43M-5.92M-2.46M-4.83M-6.71M-12.89M-18.78M-21.84M-24.74M-23.73M
Net Interest Income-2.48M-179.84K-16.57K235.57K67.36K-10.07K484K1.1M694K463K
Interest Income36800235.57K67.36K0484K1.1M694K463K
Interest Expense2.48M179.84K16.57K0010.07K0000
Other Income/Expense1.14M32.19K2.57M235.57K67.36K2.17M484K1.13M694K463K
Pretax Income
-5.29M▲ 0%
-5.89M▼ 11.4%
116.76K▲ 102.0%
-4.59M▼ 4032.4%
-6.65M▼ 44.8%
-10.72M▼ 61.2%
-18.29M▼ 70.7%
-20.71M▼ 13.2%
-24.05M▼ 16.1%
-23.63M▲ 0%
Pretax Margin %-16.44%-18.9%0.4%-15.89%-24.96%-30.6%-64.99%-77.37%-89.33%-78.56%
Income Tax0000000000
Effective Tax Rate %0%0%0%0%0%0%0%0%0%0%
Net Income
-5.29M▲ 0%
-5.89M▼ 11.4%
116.76K▲ 102.0%
-4.59M▼ 4032.4%
-6.65M▼ 44.8%
-10.72M▼ 61.2%
-18.29M▼ 70.7%
-20.71M▼ 13.2%
-24.05M▼ 16.1%
-23.63M▲ 0%
Net Margin %-16.44%-18.9%0.4%-15.89%-24.96%-30.6%-64.99%-77.37%-89.33%-78.56%
Net Income Growth %28.1%-11.36%101.98%-4032.38%-44.76%-61.23%-70.7%-13.24%-16.09%-9.54%
Net Income (Continuing)-5.29M-5.89M116.76K-4.59M-6.65M-10.72M-18.29M-20.71M-24.05M-23.63M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)
-0.24▲ 0%
-0.26▼ 8.3%
0.00▲ 100.8%
-0.07▼ 3150.0%
-0.11▼ 63.9%
-0.16▼ 45.5%
-0.26▼ 62.5%
-0.27▼ 3.8%
-0.30▼ 11.1%
-0.26▲ 0%
EPS Growth %31.43%-8.33%100.85%--63.93%-45.45%-62.5%-3.85%-11.11%-3.38%
EPS (Basic)-0.24-0.260.00-0.07-0.11-0.16-0.26-0.27-0.30-
Diluted Shares Outstanding21.81M22.61M52.08M63.05M72.75M75.56M76.06M80.7M85.18M92.01M
Basic Shares Outstanding21.81M22.61M52.08M63.05M72.75M75.56M76.06M80.7M85.18M92.01M
Dividend Payout Ratio----------

STXS Balance Sheet

Stereotaxis, Inc. (STXS) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Total Current Assets19.4M9.87M17.97M38.83M52.72M51.39M43.25M33.27M26.44M26.66M
Cash & Short-Term Investments8.5M3.69M10.8M30.18M43.94M38.74M28.43M19.82M12.22M10.51M
Cash Only8.5M3.69M10.8M30.18M43.94M38.74M8.59M19.82M12.22M10.51M
Short-Term Investments00000019.84M000
Accounts Receivable4.67M4.29M5.02M5.33M3.52M5.41M5.09M3.82M3.82M5.33M
Days Sales Outstanding52.9550.2562.4567.3148.1856.3466.0152.1151.8554.23
Inventory5.38M1.15M1.19M1.85M3.3M4.43M7.88M8.43M8.33M10.15M
Days Inventory Outstanding260.8638.9376.08109.89156.94137.25297.07258.21246.74245.02
Other Current Assets0000250.62K570K525K623K1.28M0
Total Non-Current Assets1.56M796.59K542.06K4.75M2.74M9.6M10.17M8.64M20.29M18.92M
Property, Plant & Equipment1.09M592.69K343.69K4.54M2.43M8.37M9.21M8.29M9.06M8.21M
Fixed Asset Turnover29.61x52.55x85.39x6.37x10.96x4.19x3.05x3.23x2.97x3.48x
Goodwill000000003.76M3.76M
Intangible Assets436.57K159.47K0000007.36M6.67M
Long-Term Investments0000000219K00
Other Non-Current Assets39.24K44.43K198.37K218.1K308.51K1.23M952K137K107K603K
Total Assets
20.97M▲ 0%
10.67M▼ 49.1%
18.51M▲ 73.6%
43.58M▲ 135.4%
55.46M▲ 27.2%
60.98M▲ 10.0%
53.41M▼ 12.4%
41.91M▼ 21.5%
46.72M▲ 11.5%
45.59M▲ 0%
Asset Turnover1.53x2.92x1.59x0.66x0.48x0.57x0.53x0.64x0.58x0.67x
Asset Growth %9.04%-49.12%73.57%135.41%27.24%9.97%-12.42%-21.54%11.49%31.16%
Total Current Liabilities35.65M30.13M10.19M12.16M13.57M13.26M14.29M13.25M21.6M20.37M
Accounts Payable2.62M1.65M1.73M2.1M1.61M4.19M3.27M3.19M5.67M4.68M
Days Payables Outstanding127.1656.14110.22124.8676.61129.7123.3497.75167.87152.73
Short-Term Debt00001.19M00000
Deferred Revenue (Current)8.75M5.7M5.83M5.09M5.28M6.28M7.34M7.7M7.85M13.69M
Other Current Liabilities19.79M19.57M00157.62K0163K04.59M13.1M
Current Ratio0.54x0.33x1.76x3.19x3.88x3.87x3.03x2.51x1.22x1.22x
Quick Ratio0.39x0.29x1.65x3.04x3.64x3.54x2.47x1.88x0.84x0.84x
Cash Conversion Cycle186.6533.0328.3152.34128.5163.9239.74212.56130.72146.52
Total Non-Current Liabilities842.74K1.15M1.05M2.9M1.65M8.3M7.19M6.74M13.69M13.68M
Long-Term Debt0000973.25K00000
Capital Lease Obligations0002.09M05.84M5.49M5.06M5.44M20.8M
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities320.41K535.37K641.46K255.52K131.23K218K51K43K6.19M30.43M
Total Liabilities36.5M31.27M11.24M15.06M15.23M21.56M21.48M19.99M35.29M34.05M
Total Debt0004.34M4.45M6.11M5.86M5.49M6.01M5.58M
Net Debt-8.5M-3.69M-10.8M-25.84M-39.49M-32.63M-2.73M-14.33M-6.21M-4.92M
Debt / Equity---0.15x0.11x0.15x0.18x0.25x0.53x0.53x
Debt / EBITDA----------0.25x
Net Debt / EBITDA---------0.22x
Interest Coverage-2.59x-32.92x-148.32x---1279.71x----
Total Equity
-15.53M▲ 0%
-20.61M▼ 32.7%
7.27M▲ 135.3%
28.52M▲ 292.3%
40.23M▲ 41.0%
39.42M▼ 2.0%
31.93M▼ 19.0%
21.92M▼ 31.3%
11.43M▼ 47.8%
11.53M▲ 0%
Equity Growth %11.89%-32.7%135.29%292.27%41.03%-2%-19.01%-31.35%-47.85%-195.66%
Book Value per Share-0.71-0.910.140.450.550.520.420.270.130.13
Total Shareholders' Equity-15.53M-20.61M7.27M28.52M40.23M39.42M31.93M21.92M11.43M11.53M
Common Stock22.06K22.81K59.06K68.53K73.69K75K75K81K85K91K
Retained Earnings-471.25M-477.13M-476.72M-481.31M-487.96M-498.68M-516.97M-537.68M-561.73M-577.84M
Treasury Stock-206K-206K-206K-206K-206K-206K-206K-206K-206K-206K
Accumulated OCI-5.96M-5.96M-5.96M0000000
Minority Interest0000000000

STXS Cash Flow Statement

Stereotaxis, Inc. (STXS) cash flow — operating, investing & free cash flow history

Line itemDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Cash from Operations-6.56M-4.67M-2.55M-4.62M-3.51M-2.95M-8.41M-9.14M-8.5M-8.5M
Operating CF Margin %-20.4%-15.01%-8.68%-15.97%-13.19%-8.41%-29.9%-34.14%-31.57%-
Operating CF Growth %-159.55%28.77%45.52%-81.29%23.93%16.11%-185.64%-8.6%7.02%158.08%
Net Income-5.29M-5.89M116.76K-4.59M-6.65M-10.72M-18.29M-20.71M-24.05M-23.63M
Depreciation & Amortization566.93K753.68K579.02K122.74K126.21K106K429K595K969K1.13M
Stock-Based Compensation1.37M768.68K560.97K1.33M3.17M9.36M10.58M10.62M10.26M7.47M
Deferred Taxes-3.62M3.84M-2.17M0000000
Other Non-Cash Items674.1K100K24.66K2.34M2.34M-1.83M-25K-256K1.81M5.84M
Working Capital Changes-259.16K-4.24M-1.65M-3.82M-2.5M135K-1.1M612K2.5M739K
Change in Receivables1.71M378.7K-733.86K-308.47K1.81M-1.89M316K1.27M691K2.58M
Change in Inventory-853.17K285.41K-365.14K-655.86K-1.45M-1.14M-2.91M-550K677K-1.76M
Change in Payables782.88K-968.91K72.26K372.74K-490.46K1.43M-169K218K758K-1.71M
Cash from Investing-410.18K-81.58K-265.48K-29.49K-70.9K-1.4M-22.09M19.77M74K-25K
Capital Expenditures-410.18K-81.58K-265.48K-29.49K-70.9K-1.4M-2.38M-366K-34K-25K
CapEx % of Revenue1.28%0.26%0.9%0.1%0.27%3.99%8.45%1.37%0.13%-
Acquisitions00000000108K0
Investments----------
Other Investing0000000000
Cash from Financing9.88M-58.95K9.92M24.03M17.34M547K220K81K297K7.97M
Debt Issued (Net)-13.02M0002.16M00000
Equity Issued (Net)1000K41.05K57.14K1000K1000K547K220K81K297K1.22M
Dividends Paid0000000000
Share Repurchases0000000000
Other Financing-100K-100K9.86M0000000
Net Change in Cash
2.91M▲ 0%
-4.82M▼ 265.6%
7.11M▲ 247.7%
19.39M▲ 172.7%
13.76M▼ 29.0%
-3.8M▼ 127.6%
-30.29M▼ 697.9%
10.71M▲ 135.3%
-8.13M▼ 175.9%
-507K▲ 0%
Free Cash Flow
-6.97M▲ 0%
-4.76M▲ 31.8%
-2.81M▲ 40.9%
-4.65M▼ 65.2%
-3.58M▲ 22.9%
-4.34M▼ 21.2%
-10.79M▼ 148.5%
-9.51M▲ 11.9%
-8.53M▲ 10.2%
-8.47M▲ 0%
FCF Margin %-21.68%-15.27%-9.58%-16.08%-13.45%-12.4%-38.35%-35.5%-31.69%-28.18%
FCF Growth %-160.02%31.79%40.88%-65.22%22.89%-21.22%-148.51%11.93%10.25%30.73%
FCF per Share-0.32-0.21-0.05-0.07-0.05-0.06-0.14-0.12-0.10-0.10
FCF Conversion (FCF/Net Income)1.24x0.79x-21.81x1.01x0.53x0.27x0.46x0.44x0.35x0.36x
Interest Paid0000000000
Taxes Paid0000000000

STXS Key Ratios

Stereotaxis, Inc. (STXS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201620172018201920202021202220232024TTM
Return on Equity (ROE)--1.61%-25.65%-19.33%-26.91%-51.27%-76.93%-144.19%-249.4%
Return on Invested Capital (ROIC)-----294.83%-256.68%-78.23%-89.03%-289.62%-289.62%
Gross Margin76.59%65.47%80.52%78.77%71.22%66.34%65.62%55.51%54.22%53.07%
Net Margin-16.44%-18.9%0.4%-15.89%-24.96%-30.6%-64.99%-77.37%-89.33%-78.56%
Debt / Equity---0.15x0.11x0.15x0.18x0.25x0.53x0.53x
Interest Coverage-2.59x-32.92x-148.32x---1279.71x----
FCF Conversion1.24x0.79x-21.81x1.01x0.53x0.27x0.46x0.44x0.35x0.36x
Revenue Growth-14.63%-3.17%-5.77%-1.51%-7.86%31.51%-19.63%-4.89%0.55%19.61%

STXS SEC Filings & Documents

Stereotaxis, Inc. (STXS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 15, 2026·SEC

Material company update

Mar 9, 2026·SEC

Material company update

Nov 12, 2025·SEC

10-K Annual Reports

5
FY 2026

Mar 12, 2026·SEC

FY 2025

Mar 14, 2025·SEC

FY 2024

Mar 8, 2024·SEC

10-Q Quarterly Reports

6
FY 2025

Nov 12, 2025·SEC

FY 2025

Aug 13, 2025·SEC

FY 2025

May 13, 2025·SEC

STXS Frequently Asked Questions

Stereotaxis, Inc. (STXS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Stereotaxis, Inc. (STXS) reported $30.1M in revenue for fiscal year 2024. This represents a 159022% increase from $0.0M in 2002.

Stereotaxis, Inc. (STXS) grew revenue by 0.5% over the past year. Growth has been modest.

Stereotaxis, Inc. (STXS) reported a net loss of $23.6M for fiscal year 2024.

Dividend & Returns

Stereotaxis, Inc. (STXS) has a return on equity (ROE) of -144.2%. Negative ROE indicates the company is unprofitable.

Stereotaxis, Inc. (STXS) had negative free cash flow of $8.5M in fiscal year 2024, likely due to heavy capital investments.

Explore More STXS

Stereotaxis, Inc. (STXS) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.